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Anandamide (arachidonylethanolamide; AnNH) has
important neuromodulatory and immunomodulatory
activities. This lipid is rapidly taken up and hydrolyzed
to arachidonate and ethanolamine in many organisms.
As yet, AnNH inactivation has not been studied in hu-
mans. Here, a human brain fatty-acid amide hydrolase
(FAAH) has been characterized as a single protein of 67
kDa with a pI of 7.6, showing apparent Km and Vmax
values for AnNH of 2.0 6 0.2 mM and 800 6 75
pmolzmin21zmg of protein21, respectively. The optimum
pH and temperature for AnNH hydrolysis were 9.0 and
37 °C, respectively, and the activation energy of the re-
action was 43.5 6 4.5 kJzmol21. Hydro(pero)xides de-
rived from AnNH or its linoleoyl analogues by lipoxyge-
nase action were competitive inhibitors of human brain
FAAH, with apparent Ki values in the low micromolar
range. One of these compounds, linoleoylethanolamide
is the first natural inhibitor (Ki 5 9.0 6 0.9 mM) of FAAH
as yet discovered. An FAAH activity sharing several bio-
chemical properties with the human brain enzyme was
demonstrated in human neuroblastoma CHP100 and
lymphoma U937 cells. Both cell lines have a high affinity
transporter for AnNH, which had apparent Km and Vmax
values for AnNH of 0.20 6 0.02 mM and 30 6 3
pmolzmin21zmg of protein21 (CHP100 cells) and 0.13 6
0.01 mM and 140 6 15 pmolzmin21zmg of protein21 (U937
cells), respectively. The AnNH carrier of both cell lines
was activated up to 170% of the control by nitric oxide.
Anandamide (arachidonylethanolamide; AnNH)1 is an en-
dogenous lipid that binds to cannabinoid CB1 and CB2 recep-
tors, which are mainly found in the central nervous system and
in peripheral immune cells. It mimics the pharmacological
effects of D9-tetrahydrocannabinol, the active principle of hash-
ish and marijuana (1, 2). AnNH formation occurs mainly
through phosphodiesterase-mediated cleavage of N-arachido-
noylphosphatidylethanolamine (3, 4), although a direct synthe-
sis from arachidonic acid and ethanolamine has also been de-
scribed (5, 6). AnNH can be released from depolarized neurons
(3). Upon binding to CB1 receptors, AnNH induces inhibition of
forskolin-induced cAMP accumulation, inhibition of N-type
Ca21 channels, and activation of mitogen-activated protein
kinase signal transduction pathway (reviewed in Ref. 7) and
increases protein tyrosine phosphorylation (8). Activation of
the CB2 receptor leads to inhibition of adenylate cyclase and
activation of the mitogen-activated protein kinase signaling (9).
Interestingly, AnNH binding to cannabinoid receptors is cou-
pled to nitric oxide (NO) release in the central nervous system
of invertebrates and in peripheral immune cells of both inver-
tebrates and humans (10).
The pharmacological effects of AnNH on CB1 and CB2 re-
ceptors depend on the life span of the lipid in the extracellular
space, which is limited by a rapid and selective process of
cellular uptake, followed by intracellular degradation of AnNH
to ethanolamine and arachidonic acid by the enzyme fatty-acid
amide hydrolase (FAAH). Both components of the inactivation
process of AnNH are the subject of active investigation. AnNH
uptake has been characterized in rat neuronal cells (3, 11, 12)
and rat basophilic leukemia (RBL-2H3) cells (13). FAAH has
been demonstrated and partially characterized in rat, porcine,
and dog brains (14–16). Furthermore, FAAH activity has been
shown in one “neuronal” cell line, namely mouse neuroblas-
toma N18TG2 (17), and in one “non-neuronal” cell line, namely
RBL-2H3 (13). The FAAH gene has recently been cloned from
rat, mouse, and human liver cDNAs, allowing molecular mass
determination and substrate specificity analysis of the enzyme
(18, 19). As yet, no information is available on the activity of
human FAAH or on AnNH uptake in human cells. This
prompted us to investigate some biochemical properties of
FAAH from human brain and human neuronal and immune
cells, i.e. neuroblastoma CHP100 and lymphoma U937 cells.
AnNH uptake was characterized in these two cell types to gain
information on the AnNH inactivation process in humans. The
cell lines chosen are widely used as experimental models for
neuronal (20) and immune (21) tissues. In these two cell types,
AnNH uptake was demonstrated and characterized.
Taken together, the results reported here represent the first
biochemical characterization of human brain FAAH. Most
properties of this enzyme are shared by FAAH found in human
neuronal and immune cells in culture. Remarkably, both cell
lines seem to inactivate AnNH in the same way, which
strengthens the concept of a neuroimmune axis in humans,
which is evident, for instance, in the “axon-reflex” model for
neurogenic inflammation (13). Possible implications of FAAH
activity and expression in brain pathology are also discussed.
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EXPERIMENTAL PROCEDURES
Materials—Chemicals were of the purest analytical grade. Anandamide
(arachidonylethanolamide), arachidonic acid, ethanolamine, phenylmethyl-
sulfonyl fluoride (PMSF), iodoacetic acid, N-ethylmaleimide, carbonyl cya-
nide m-chlorophenylhydrazone (CCCP), and sodium nitroprusside (SNP)
were purchased from Sigma. S-Nitroso-N-acetylpenicillamine was from Re-
search Biochemicals International, and spermine NONOate ((Z)-1-{N-[3-
aminopropyl]-N-[4-(3-aminopropylammonio)butyl]amino}diazen-1-ium-1,2-
diolate) was from Alexis Corp. (La¨ufelfingen, Switzerland). Leukotriene B4
and prostaglandin E2 were from Cayman Chemical Co., Inc. [1-
14C]AnNH
was synthesized from ethanolamine and [1-14C]arachidonic acid (52 mCi/
mmol; NEN DuPont de Nemours, Ko¨ln, Germany) as reported (22).
Linoleoylethanolamide ((9Z,12Z)-octadeca-9,12-dienoylethanolamide;
ODNHEtOH), linoleoylamide ((9Z,12Z)-octadeca-9,12-dienoylamide;
ODNH2), linoleoylmethylamide ((9Z,12Z)-octadeca-9,12-dienoylmethyla-
mide; ODNHMe), and their 13-hydroxy derivatives (13-HODNHEtOH, 13-
HODNH2, and 13-HODNHMe) were synthesized and characterized (purity
.96% by gas-liquid chromatography) as reported (23). 15-Hydro(pero)xy-
anandamide (15-hydro(pero)xyeicosa-(5Z,8Z,11Z,13E)-tetraenoylethanol-
amide; 15-H(P)AnNH; purity .96%) and 11-hydro(pero)xyanandamide (11-
H(P)AnNH; a mixture of 45% 11-H(P)AnNH, 24% 5-H(P)AnNH, 18% 15-
H(P)AnNH, 9% 8/9-H(P)AnNH, and 4% 12-H(P)AnNH by reversed-phase
high performance liquid chromatography) were a gift from Guus van Zad-
elhof (Bijvoet Center for Biomolecular Research, Utrecht University).
Biological Material—Human brain specimens were obtained from
five different male patients (aged 73–77) undergoing surgical opera-
tions to remove meningioma tumors. Brain tissues were removed and
donated by Prof. R. Giuffre` and Dr. G. De Caro (Neurosurgery Division,
University of Rome Tor Vergata, Sant’Eugenio Hospital, Rome, Italy).
In four cases, the perilesional white matter surrounding the tumor area
was removed (1 g of fresh tissue in total) and used for FAAH charac-
terization. In one case, both meningioma and perilesional white matter
(0.1 g of each fresh tissue) were removed and used to compare FAAH
activity and expression in meningioma and healthy brain.
Human neuroblastoma CHP100 cells were cultured as reported (20)
in a 1:1 mixture of Eagle’s minimal essential medium plus Earle’s salts
and Ham’s F-12 medium (Flow Laboratories Ltd., Irvine, United King-
dom) supplemented with 15% heat-inactivated fetal bovine serum, 1.2
g/liter sodium bicarbonate, 15 mM Hepes, 2 mM L-glutamine, and 1%
nonessential amino acids. Human lymphoma U937 cells, a gift from Dr.
E. Faggioli (Department of Public Health and Cell Biology, University
of Rome Tor Vergata), were cultured in RPMI 1640 medium (Gibco,
Paisley, United Kingdom) supplemented with 25 mM Hepes, 2.5 mM
sodium pyruvate, 100 units/ml penicillin, 100 mg/ml streptomycin, and
10% heat-inactivated fetal calf serum (21). Both CHP100 and U937 cells
were maintained at 37 °C in a humidified 5% CO2 atmosphere.
Assay of FAAH—Immediately after surgical removal, human brain
specimens were washed in phosphate-buffered saline and homogenized
with an UltraTurrax T25 in 50 mM Tris-HCl and 1 mM EDTA, pH 7.4
(buffer A), at a 1:10 homogenization ratio (fresh weight/volume). Mem-
branes from these tissue homogenates were then prepared as described
(15, 17). The final pellet, containing most of the FAAH activity (13, 17,
24), was resuspended in ice-cold buffer A at a protein concentration of
1 mg/ml and stored at 280 °C until use. Both CHP100 and U937 cells
(3 3 108/sample) were collected in phosphate-buffered saline and cen-
trifuged at 1000 3 g for 10 min. The dry pellet was resuspended in 30
ml of ice-cold buffer A and sonicated on ice three times for 10 s, with
10-s intervals, using a Vibracell sonifier (Sonics & Materials Inc.) with
a microtip at maximum power. The homogenate was then centrifuged
sequentially as described above for the human brain, and the final
pellet was stored at 280 °C in buffer A at a protein concentration of 1
mg/ml until use.
The assay of FAAH (arachidonylethanolamide amidohydrolase, EC
3.5.1.4) activity was performed by reversed-phase high performance
liquid chromatography (HPLC) as recently described (22). Thermal
stability and pH dependence of FAAH activity were studied as de-
scribed (17). Activation energy values were calculated as reported (25).
Kinetic and inhibition studies were performed using different concen-
trations of [1-14C]AnNH (in the 0–21 mM range) and two different
concentrations (10 and 20 mM) of each inhibitor to calculate the kinetic
parameters. Fitting of the experimental points to a Lineweaver-Burk
plot by a linear regression program (Kaleidagraph Version 3.0) yielded
straight lines with r values .0.95.
The assay of the FAAH synthase activity was performed by meas-
uring the formation of [1-14C]AnNH from [1-14C]arachidonic acid and
ethanolamine as reported (5). Tissue or cell homogenates (20 mg of
proteins/test) were incubated for 15 min at 37 °C in 200 ml of 50 mM
Tris-HCl, pH 9.0, containing 10 mM [1-14C]arachidonic acid (52 mCi/
mmol) and 2 mM ethanolamine. The reaction was stopped, and the
products were extracted and analyzed by reversed-phase HPLC follow-
ing the same procedure as described above for the hydrolase activity.
FAAH synthase activity is expressed as picomoles of AnNH formed per
min/mg of protein. The effect of various compounds on the hydrolase or
synthase activity of FAAH was determined by adding each substance
directly to the assay buffer at the indicated concentrations.
Immunochemical Analysis—SDS-polyacrylamide gel electrophoresis
(12%) was performed under reducing conditions in a Mini-Protean II
apparatus (Bio-Rad) with 0.75-mm spacer arms (26). Rainbow molecu-
lar mass markers (Amersham International, Buckinghamshire, United
Kingdom) were phosphorylase b (97.4 kDa), bovine serum albumin
(66.0 kDa), and ovalbumin (46.0 kDa). Native isoelectric focusing was
performed in the Mini-Protean II apparatus using a 5% polyacrylamide
gel containing ampholytes in the pH range 5.0–9.0 (Sigma) as described
(27). Isoelectric focusing was calibrated by running the following pI
markers (Sigma): lentil (Lens culinaris) lectin (pI 8.8, 8.6, and 8.2),
myoglobin from horse heart (pI 7.2 and 6.8), carbonic anhydrase I from
human erythrocytes (pI 6.6), and carbonic anhydrase II from bovine
erythrocytes (pI 5.9). Human brain homogenates (20 mg/lane), prepared
as described above for FAAH assay, were subjected to either SDS-
FIG. 1. Dependence of FAAH activity on anandamide concen-
tration. In A, FAAH activity was assayed at various anandamide
concentrations in human brain (l) and human lymphoma U937 cells
() in culture. In B, FAAH activity was assayed in human neuroblas-
toma CHP100 cells (f) in culture. In both panels, FAAH activity was
measured at pH 9.0 and 37 °C.
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polyacrylamide gel electrophoresis or isoelectric focusing, and then slab
gels were electroblotted onto 0.45-mm nitrocellulose filters (Bio-Rad)
using a Mini-TransBlot apparatus (Bio-Rad) as reported (26). Immuno-
detection of FAAH on nitrocellulose filters was performed with specific
anti-FAAH polyclonal antibodies (diluted 1:200), raised in rabbits
against the conserved FAAH sequence VGYYETDNYTMPSPAMR (19),
conjugated to ovalbumin. This peptide antigen and the anti-FAAH
polyclonal antibodies were prepared by Primm s. r. l. (Milan, Italy).
Goat anti-rabbit alkaline phosphatase conjugate (Bio-Rad; diluted
1:2000) was used as secondary antibody, and immunoreactive bands
were stained with the alkaline phosphatase staining solution according
to the manufacturer’s instructions (Bio-Rad).
Enzyme-linked immunosorbent assay (ELISA) was performed by
coating the plate with human brain homogenate (20 mg/well), prepared
as described above for the FAAH assay. Anti-FAAH polyclonal antibod-
ies were used as primary antibody (diluted 1:300), and goat anti-rabbit
alkaline phosphatase conjugate as secondary antibody (diluted 1:2000).
Color development of the alkaline phosphatase reaction was measured
at 405 nm using p-nitrophenyl phosphate as substrate. For peptide
competition experiments, the peptide antigen was preincubated with a
1000-fold molar excess of anti-FAAH polyclonal antibodies for 30 min at
room temperature before adding the antibodies to the wells (18). Con-
trols were carried out using non-immune rabbit serum and included
wells coated with different amounts of bovine serum albumin.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and
Sequencing—2–5 3 106 cells or 20 mg of tissue were used to isolate total
RNA by means of the S.N.A.P.TM total RNA isolation kit (Invitrogen).
Control reactions were carried out to ensure complete removal of
genomic DNA. RT-PCRs were performed using the EZ rTth RNA PCR
kit (Perkin-Elmer) following the manufacturer’s instructions. The reac-
tion conditions were carefully examined to stop the reaction during the
exponential phase of amplification of each gene. Briefly, 100 ng (for the
amplification of FAAH) or 0.4 ng (for 18 S rRNA) of total RNA were
reversibly transcribed and amplified in the same tube in a total reaction
volume of 10 ml in the presence of 3 mCi of [a-32P]dCTP (3000 Ci/mmol;
Amersham International). The amplification parameters were as fol-
lows: 2 min at 95 °C, 45 s at 95 °C, 30 s at 55 °C, and 30 s at 60 °C.
Linear amplification was observed after 20 cycles. The primers were as
follows: (1)59-TGGAAGTCCTCCAAAAGCCCAG and (2)59-TGTC-
CATAGACACAGCCCTTCAG for FAAH and (1)59-AGTTGCTGCAGT-
TAAAAAGC and (2)59-CCTCAGTTCCGAAAACCAAC for 18 S rRNA.
Five ml of the reaction mixture were electrophoresed on a 6% poly-
acrylamide gel, which was then dried and subjected to autoradiography.
Products were validated by size determination and sequencing. For
TABLE I
Inhibition of human brain FAAH activity by different anandamide products and analogues
Apparent inhibition constant (Ki) values were calculated by Lineweaver-Burk profiles of AnNH hydrolysis by FAAH. All compounds were
reversible competitive inhibitors of FAAH activity. Total activity of human brain FAAH was determined using 10 mM AnNH or congeners as
substrate.
a 100% 5 750 6 70 pmol z min21 z mg of protein21.
b 11-HPAnNH was a mixture of 11-HPAnNH (45%), 5-HPAnNH (24%), 15-HPAnNH (18%), 8/9-HPAnNH (9%), and 12-HPAnNH (4%).
c 11-HAnNH was the same mixture as 11-HPAnNH, reduced with NaBH4.
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quantitation of the RT-PCR products, bands were excised from the gel
and counted in an LKB1214 Rackbeta scintillation counter (Amersham
Pharmacia Biotech, Uppsala, Sweden). Linear amplification sequencing
was performed using a CyclistTM DNA sequencing kit (Stratagene)
according to the manufacturer’s instructions. RT-PCR products for se-
quencing were prepared without [a-32P]dCTP and sequenced with the
same primers used for amplification after labeling them with
[g-32P]dATP (3000 Ci/mmol; Amersham International).
Determination of Anandamide Uptake—The uptake of [1-14C]AnNH
(52 mCi/mmol) in intact CHP100 or U937 cells was studied essentially
as described (13). CHP100 and U937 cells were resuspended in their
serum-free culture media at a density of 1 3 106 cells/ml. Cell suspen-
sions (2 ml/test) were incubated for different time intervals at 37 °C
with 100 nM [1-14C]AnNH; then they were washed three times in 2 ml
of culture medium containing 1% bovine serum albumin and were
finally resuspended in 200 ml of phosphate-buffered saline. Membrane
lipids were then extracted (28), resuspended in 0.5 ml of methanol, and
mixed with 3.5 ml of Sigma-Fluor liquid scintillation mixture for non-
aqueous samples (Sigma), and radioactivity was measured in an
LKB1214 Rackbeta scintillation counter. To discern non-protein-medi-
ated from protein-mediated transport of AnNH into cell membranes,
control experiments were carried out at 4 °C (13). Incubations (15 min)
were also carried out with different concentrations of [1-14C]AnNH (in
the 0–750 nM range) to determine apparent Km and Vmax of the uptake
by Lineweaver-Burk analysis (in this case, the uptake at 4 °C was
subtracted from that at 37 °C). The Q10 value was calculated as the
ratio of AnNH uptake at 30 and 20 °C (11). AnNH uptake is expressed
as picomoles of AnNH taken up per min/mg of protein. The effect of
different compounds on AnNH uptake was determined by adding each
substance directly to the incubation medium at the indicated concen-
trations. In the case of CCCP, cells were preincubated with 50 mM CCCP
for 15 min at 37 °C before the addition of [1-14C]AnNH to abolish
mitochondrial transmembrane potential (29). Cell viability after each
treatment was checked with trypan blue and found to be higher than
90% in all cases. It is noteworthy that no specific binding of
[3H]CP55940, a potent cannabinoid, was obtained with plasma mem-
branes of CHP100 cells,2 and U937 cells express hardly detectable
levels of CB1 mRNA and very low levels of CB2 mRNA (21); thus,
[1-14C]AnNH binding to CB receptors is not likely to interfere in the
uptake experiments (11, 13).
Data Analysis—Data reported in this paper are the means 6 S.D. of
at least three independent determinations, each performed in dupli-
cate. Statistical analysis was performed by the Student’s t test, elabo-
rating experimental data by means of the InStat program (GraphPAD
Software for Science).
RESULTS
Characterization of FAAH in Human Brain and Human
CHP100 and U937 Cells—Pilot experiments indicated that
human brain FAAH activity was linearly dependent on the
amount of tissue homogenate (in the range 0–30 mg of protein)
and the incubation time of the reaction (in the range 0–30 min),
whereas it depended on AnNH concentration according to
Michaelis-Menten kinetics (Fig. 1A) (data not shown), yielding
an apparent Km of 2.0 6 0.2 mM and a Vmax of 800 6 75
pmolzmin21zmg of protein21. The activity of FAAH was assayed
in the pH range 5.0–11.0 and in the temperature range 20–
65 °C, showing an optimum pH and temperature at 9.0 and
37 °C, respectively. Arrhenius diagrams of AnNH hydrolysis by
FAAH in the temperature range 20–45 °C allowed us to calcu-
late an activation energy of 43.5 6 4.5 kJzmol21.
Hydroxylated AnNH derivatives and the linoleoyl analogues
of AnNH were competitive inhibitors of human brain FAAH,
with apparent Ki values ranging from 3.2 to 24.5 mM (Table I).
2 M. Maccarrone, A. M. Paoletti, G. Bagetta, and A. Finazzi Agro`,
unpublished results.
FIG. 2. Electrophoretic properties of human brain FAAH. Hu-
man brain extracts (20 mg/lane) were subjected to either SDS-polyacryl-
amide gel electrophoresis (left panel) or isoelectric focusing (right pan-
el). Slab gels were then electroblotted onto nitrocellulose filters, and
FAAH was detected as an immunoreactive band with specific anti-
FAAH polyclonal antibodies. Molecular mass markers and pI markers
are shown.
TABLE II
Inhibition of FAAH activity and [14C]anandamide uptake in human brain and human CHP100 and U937 cells
FAAH activity was determined using 10 mM AnNH as substrate. For uptake experiments, cells (2 3 106) were incubated for 15 min at 37 °C with
100 nM [14C]AnNH in the presence of each compound. Activity and uptake values are expressed as percentage of the untreated controls, arbitrarily
set to 100 (see below for absolute values). Results on FAAH activity in CHP100 and U937 cells were superimposable; thus, FAAH activity in
CHP100 cells was omitted for the sake of clarity.
Compound
FAAH activity Anandamide uptake
Brain U937 CHP100 U937
% %
None 100a 100b 100c 100d
Arachidonic acid (100 mM) 18 6 2 16 6 2 100 6 10 100 6 10
Ethanolamine (100 mM) 83 6 8 80 6 8 95 6 10 88 6 9
15-HAnNH (10 mM) 33 6 3 50 6 5 90 6 9 87 6 9
ODNHEtOH (10 mM) 56 6 6 62 6 6 89 6 9 85 6 9
13-HODNHEtOH (10 mM) 26 6 3 43 6 4 80 6 8 82 6 8
Leukotriene B4 (1 mM) ND
e ND 105 6 10 100 6 10
Prostaglandin E2 (10 mM) ND ND 105 6 10 105 6 10
PMSF (100 mM) 6 6 1 8 6 1 50 6 5 52 6 5
Iodoacetic acid (100 mM) 10 6 1 12 6 1 50 6 5 48 6 5
N-Ethylmaleimide (100 mM) 15 6 2 18 6 2 55 6 5 50 6 5
CCCP (50 mM) ND ND 85 6 9 86 6 9
SNP (5 mM) 87 6 9 85 6 9 170 6 17 See Fig. 5B
SNAP (5 mM) 85 6 9 87 6 9 175 6 18 See Fig. 5B
SPER-NO (5 mM) 88 6 9 84 6 9 172 6 17 See Fig. 5B
a 100% 5 750 6 70 pmol z min21 z mg of protein21.
b 100% 5 390 6 40 pmol z min21 z mg of protein21.
c 100% 5 7.0 6 0.7 pmol z min21 z mg of protein21.
d 100% 5 53.0 6 5.5 pmol z min21 z mg of protein21.
e ND, not determined; SNAP, S-nitroso-N-acetylpenicillamine; SPER-NO, spermine NONOate.
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These AnNH congeners were also alternate substrates of
FAAH, yielding total activities that ranged from 85% (11-
HAnNH) to 49% (13-HODNH2) of the activity obtained with
AnNH itself (Table I). The substrate specificity of FAAH from
human brain resembled that of the enzyme from mouse or rat
brain (18, 19, 22).
Western blotting showed that anti-FAAH polyclonal antibod-
ies specifically recognized a single immunoreactive band in
brain homogenates, corresponding to a molecular mass of ;67
kDa and an isoelectric point of ;7.6 (Fig. 2).
Human neuronal (CHP100) and immune (U937) cells in cul-
ture also showed FAAH activity, with pH and temperature
profiles superimposable to those observed with the human
brain enzyme (data not shown). Both cell lines showed an
FAAH activity (Fig. 1, A and B) characterized by apparent Km
and Vmax values of 6.5 6 0.6 mM and 32 6 3 pmolzmin
21zmg of
protein21 (CHP100) and 6.5 6 0.6 mM and 520 6 50
pmolzmin21zmg of protein21 (U937) for AnNH. The activation
energy of AnNH hydrolysis by FAAH in CHP100 or U937 cells
(45.0 6 4.5 kJzmol21 in either case) was the same as the human
brain enzyme. Moreover, 15-HAnNH, ODNHEtOH, and 13-
HODNHEtOH competitively inhibited FAAH activity in both
cell lines, with apparent Ki values of 4.5 6 0.4, 11.1 6 0.9, and
6.1 6 0.5 mM (CHP100) and 3.8 6 0.4, 10.5 6 1.0, and 4.5 6 0.4
mM (U937), respectively. Excess (100 mM) arachidonic acid, but
not ethanolamine, strongly inhibited FAAH activity in all hu-
man sources tested, in line with previous findings on mouse
FAAH (17). Alkylating agents such as PMSF, iodoacetic acid,
and N-ethylmaleimide (at 100 mM) almost abolished FAAH
activity in all sources (Table II). The NO donors SNP, S-nitro-
so-N-acetylpenicillamine, and spermine NONOate (at millimo-
lar concentrations that release nanomolar concentrations of
NO in solution) (30, 31) hardly affected the hydrolase activity
(Table II).
An anandamide synthase activity (32) was also present in
the materials from human sources. The following maximum
reaction rates were found: 70 6 7 (human brain), 24.5 6 2.5
(CHP100), and 40 6 4 (U937) pmolzmin21zmg of protein21.
These values were ;5-fold (CHP100 cells) to 10-fold (human
brain and U937 cells) lower than the hydrolase activity under
the same assay conditions (i.e. 10 mM arachidonic acid and 20
mg of proteins), as shown in Fig. 1. Nevertheless, the synthase
was affected by 15-HAnNH, ODNHEtOH, 13-HODNHEtOH,
PMSF, and SNP in the same way as the hydrolase activity
(Table II), both in human brain and human cell lines (data not
shown).
Expression of FAAH in Human Brain and Human CHP100
and U937 Cells—The analysis of FAAH expression in human
brain and human cells was performed at the protein (by
ELISA) and mRNA (by RT-PCR) levels. The amount of FAAH
protein in human brain was ;2- or 10-fold higher than that
observed in U937 or CHP100 cells, respectively (Fig. 3A). This
quantitation was validated by antigen competition experi-
ments (18), showing that immunoreaction of the anti-FAAH
polyclonal antibodies with the enzyme protein in human homo-
genates was specific (Fig. 3A). RT-PCR analysis showed similar
differences in the mRNA levels (Fig. 3, A and B). Sequencing of
FIG. 3. Quantitation of FAAH in human brain and human
CHP100 and U937 cells. A, tissue or cell homogenates (20 mg/well)
were subjected to ELISA using specific anti-FAAH polyclonal antibod-
ies (white bars). Antigen competition ELISA (hatched bars) was per-
formed by preincubating anti-FAAH polyclonal antibodies with a 1000-
fold molar excess of peptide antigen. Absorbance values are expressed
as percentage of the maximum, arbitrarily set to 100 (100% corresponds
to 0.760 6 0.080 absorbance units at 405 nm). FAAH mRNA levels
(dotted bars) were quantitated by liquid scintillation counting and are
expressed as percentage of the maximum, arbitrarily set to 100 (100%
5 20,000 6 2000 cpm). The radioactivity of the bands corresponding to
18 S rRNA (see B) was identical in all samples (5000 6 500 cpm). B,
FAAH mRNA (50 ng/lane) and 18 S rRNA (0.2 ng/lane) were amplified
by RT-PCR and electrophoresed on 6% polyacrylamide gels. C, shown is
the conserved amino acid sequence deduced from FAAH mRNA isolated
from human brain or human CHP100 or U937 cells. The sequence
contains the amidase consensus sequence (amino acids 215–246) typical
of all FAAHs as yet known.
FIG. 4. Comparison of FAAH activity and expression in human
healthy brain and meningioma. FAAH activity (white bars) was
measured using 10 mM AnNH as substrate. FAAH protein content
(hatched bars) was determined by ELISA using 20 mg of proteins/well.
Antigen competition ELISA (dotted bars) was performed by preincubat-
ing anti-FAAH polyclonal antibodies with a 1000-fold molar excess of
peptide antigen. FAAH activity and content are expressed as percent-
age of the control (healthy brain), arbitrarily set to 100 (100% 5 750 6
70 pmolzmin21zmg of protein21 for the activity; 100% 5 0.760 6 0.080
absorbance units at 405 nm for the protein content).
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the FAAH mRNA, amplified by RT-PCR from human brain or
human CHP100 or U937 cells, showed that human FAAH
possesses a completely conserved sequence between amino ac-
ids 208 and 272, which contains a typical amidase consensus
sequence (Fig. 3C).
FAAH activity and expression were measured also in human
meningioma and were compared with those found in the per-
ilesional white matter (healthy brain). AnNH hydrolysis by
meningioma FAAH followed Michaelis-Menten kinetics, with
apparent Km and Vmax values of 4.0 6 0.4 mM and 370 6 40
pmolzmin21zmg of protein21, respectively. Interestingly, the
specific activity of FAAH in human meningioma was 50% com-
pared with that in healthy brain, a value that was paralleled by
the amount of FAAH protein in the same tissues (Fig. 4).
Characterization of AnNH Uptake in Human CHP100 and
U937 Cells—Neuroblastoma CHP100 and lymphoma U937
cells were able to accumulate [14C]AnNH, a process that was
temperature-dependent (Q10 5 1.5 for both cell lines), time-de-
pendent (t1⁄2 5 5 min for both cell lines), and concentration-de-
pendent (Fig. 5A) (data not shown). [14C]AnNH uptake in
CHP100 and U937 cells was saturable (Km 5 0.20 6 0.02 and
0.13 6 0.01 mM and Vmax 5 30 6 3 and 140 6 15 pmolzmin
21zmg
of protein21, respectively); was enhanced when incubations
were carried out in the presence of the NO donors SNP, S-
nitroso-N-acetylpenicillamine, and spermine NONOate (Table
II and Fig. 5B); and was reduced in the presence of PMSF,
iodoacetic acid, or N-ethylmaleimide, each used at a 100 mM
final concentration (Table II). Enhancement of [14C]AnNH up-
take by 5 mM SNP was prevented by co-incubation with either
20 mM hemoglobin, a typical NO scavenger (20), or 100 mM
PMSF (data not shown). SNP and PMSF affected the uptake
kinetics by changing the Vmax value, but not the Km, thus
changing the catalytic efficiency (i.e. the Vmax/Km ratio) of the
transporter (Table III). On the other hand, 100 mM arachidonic
acid or ethanolamine and 10 mM 15-HAnNH, ODNHEtOH, or
13-HODNHEtOH did not significantly influence AnNH uptake
in either cell type, nor did 1 mM leukotriene B4, 10 mM prostag-
landin E2, or 50 mM CCCP (Table II).
DISCUSSION
Meningioma is a histologically benign tumor that is brain-
invasive only in 4% of cases (33). Thus, perilesional white
FIG. 5. Uptake of [14C]anandamide in intact CHP100 and U937
cells. A, dependence of [14C]AnNH uptake (15 min, 37 °C) on AnNH
concentration in human U937 (l) and CHP100 () cells. B, effect of NO
donors SNP (white bars), S-nitroso-N-acetylpenicillamine (hatched
bars), and spermine NONOate (dotted bars) on the uptake of 100 nM
[14C]AnNH in U937 cells (15 min, 37 °C). Uptake increase is expressed
as percentage over the untreated control (100% 5 53.0 6 5.5
pmolzmin21zmg of protein21).
SCHEME 1. Interaction between anandamide uptake and deg-
radation. Binding of extracellular AnNH to cannabinoid receptors
(CBR) leads to intracellular NO production, which in turn activates
transporter (T)-mediated uptake of AnNH. Once taken up, AnNH can
be rapidly cleaved by membrane-bound FAAH, releasing arachidonic
acid and ethanolamine. Alternatively, hydro(pero)xides of AnNH can be
generated by lipoxygenase (LOX) activity, leading to inhibition of
FAAH. This alternate pathway is prevented by NO, short pulses of
which are able to inhibit lipoxygenase activity. Is should be stressed
that other signaling pathways, uncoupled to AnNH binding to CB
receptors, can enhance intracellular production of NO, thus activating
the sequestration process of this lipid mediator. Therefore, cannabi-
noid-binding receptors can reside on the same cell bearing the inacti-
vation machinery or on different cells.
TABLE III
Kinetic parameters of anandamide uptake in human CHP100 and
U937 cells
Uptake of [14C]AnNH was investigated in cell suspensions (2 3 106
cells/test), either untreated or treated with the NO donor SNP or the
alkylating agent PMSF. Apparent Km and Vmax values are expressed as
micromolar and picomoles z min21 z mg of protein21, respectively.
Human cell line Km Vmax Vmax/Km
Neuroblastoma CHP100 cells 0.20 6 0.02 30 6 3 150
15 mM SNP 0.20 6 0.02 650 6 5a 250
1100 mM PMSF 0.20 6 0.02 15 6 2a 75
Lymphoma U937 cells 0.13 6 0.01 140 6 15 1077
15 mM SNP 0.13 6 0.01 230 6 22a 1769
1100 mM PMSF 0.13 6 0.01 75 6 8a 577
a p , 0.01 compared with the control.
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matter surrounding the meningioma can be considered an es-
sentially healthy brain area and was chosen in this study to
characterize FAAH. Human brain showed a remarkable FAAH
activity, and anti-FAAH antibodies recognized a single protein
of 67 kDa with an isoelectric point of 7.6, characterized here for
the first time (Fig. 2). These values were in good agreement
with the size of the full-length human liver FAAH cDNA (19)
and the isoelectric point predicted from FAAH sequence by the
GCG Sequence Analysis Software Package (46). Moreover, hu-
man brain FAAH cDNA had the same amidase consensus se-
quence (Fig. 3C) as FAAH cloned from human, mouse, and rat
livers (18, 19). It is noteworthy that the activation energy of the
AnNH hydrolysis catalyzed by FAAH from all three sources
was identical. Furthermore, the FAAH activity in human
CHP100 and U937 cells shared several other biochemical prop-
erties, such as pH and temperature dependence and inhibition
profile, with the enzyme from human brain. In addition, the
enzymes contained an identical amidase sequence. This might
indicate that the same enzyme was present in all human sam-
ples, although the participation of other enzymes cannot be
ruled out.
Human brain FAAH was further characterized with respect
to its interaction with inhibitors. Here, linoleoyl analogues of
AnNH and hydro(pero)xides generated thereof, which are
likely to be produced in vivo by brain lipoxygenases (16, 22, 23,
34), were shown to be competitive inhibitors of FAAH activity,
with apparent Ki values in the low micromolar range (Table I).
Interestingly, linoleoylethanolamide is a physiological constit-
uent of rat neurons (3) and has recently been reported to
displace [3H]CP55940, a potent cannabinoid, only at high con-
centrations (Ki . 1 mM) from cannabinoid receptors in rat brain
membranes (22). This compound might be the first natural
inhibitor of FAAH as yet discovered. It has recently been
shown, however, that oleamide, a sleep-inducing lipid, inhib-
ited FAAH activity, but as high as 100 mM oleamide was needed
to inhibit it by 50% in mouse neuroblastoma N18TG2 cells (24).
It is noteworthy that the apparent Vmax of human brain
FAAH was ;2- or 25-fold higher than that of U937 or CHP100
cells, respectively. The presence of different amounts of FAAH
in the cells could explain this observation. Indeed, the amount
of FAAH protein was 2- or 10-fold higher in human brain than
in U937 or CHP100 cells, respectively (Fig. 3A), and similar
differences were observed in the level of FAAH mRNA (Fig.
3B). Therefore, it can be suggested that a different expression
(both at the transcriptional and translational level) of the same
enzyme might be responsible for the different apparent Vmax
values of FAAH from the different human sources. A differen-
tial expression of FAAH might also be involved in human brain
pathology, as suggested by comparison of meningioma and the
surrounding (healthy) white matter (Fig. 4). This seems of
interest if one recalls that a neurotrophic effect of AnNH has
been proposed (8) and that AnNH might act as growth factor
for hematopoietic cell lines (35, 36). Therefore, a lower expres-
sion of the AnNH-hydrolyzing enzyme FAAH might be instru-
mental in prolonging AnNH-associated growth stimulus, ulti-
mately leading to cell immortalization.
To be inactivated by FAAH, AnNH has to be transported into
the cell. Recent experiments performed on rat neuronal cells (3,
11, 12), rat basophilic leukemia (RBL-2H3) cells, and mouse
J774 macrophages (13) clearly showed the presence of a high
affinity AnNH transporter in the outer cell membranes. A
similar methodology was used here to characterize, for the first
time, the AnNH uptake in human neuronal (CHP100) and
immune (U937) cells. Both cell types rapidly took up AnNH (t1⁄2
5 5 min) in a temperature-dependent (Q10 5 1.5) and saturable
way (Fig. 5A and data not shown). [14C]AnNH was taken up by
CHP100 and U937 cells with similar high affinity, but remark-
ably different velocity (Table III). Interestingly, U937 cells,
which possessed higher FAAH activity than CHP100 cells,
showed also a more efficient AnNH uptake. The affinity of the
AnNH transporter in human cells was comparable to that in
rat astrocytes (Km 5 0.32 mM) (12) and was almost an order of
magnitude higher than the affinity reported for dopamine (Km
5 1 mM) or glutamate (Km 5 1–5 mM) carriers in rat brain (37,
38). Furthermore, the uptake of AnNH in human cells was
affected by AnNH hydrolysis products, leukotriene B4, prostag-
landin E2, and alkylating agents (Table II) in much the same
way as reported for rat neuronal and non-neuronal cells (11–
13). This suggests that AnNH accumulation is selective and
mediated by a transporter other than the long chain fatty acid
transporter protein (39) or the prostaglandin transporter (40),
in keeping with recent data on the AnNH carrier of rat neurons
and astrocytes (12). AnNH uptake in human CHP100 and
U937 cells was independent of mitochondrial energy metabo-
lism because the uncoupling agent CCCP (29) hardly affected
AnNH accumulation (Table II). These results indicate that
AnNH is accumulated by a carrier-mediated facilitated diffu-
sion, as recently reported for rat cells (11). The enhancement of
AnNH uptake by the NO donor SNP (Table II) was due to
increased apparent Vmax values (up to 170% of the control
value), without changes in the apparent Km. Conversely, the
alkylating agent PMSF reduced the apparent Vmax to 50% of
the control, without changing the apparent Km (Table III). It is
tempting to suggest that the active site of the transporter may
contain a cysteine residue, which could be the target of both NO
donors and alkylating agents. The effect of co-incubation with
PMSF strengthens this hypothesis.
Altogether, the results reported here form the first charac-
terization of human brain FAAH. In addition, the observations
highlight the possible role of linoleoyl analogues of AnNH (and
hydro(pero)xides generated thereof and from AnNH itself by
lipoxygenase activity) as inhibitors of human brain FAAH. The
AnNH transporter also has been characterized for the first
time in human cells, showing that it was not affected by the
AnNH derivatives/analogues that inhibited FAAH, but was
sensitive to NO donors.
These findings give rise to a general picture of the inactiva-
tion process of AnNH in human neuronal and immune cells
(Scheme 1). AnNH is brought into the cell by a transporter
protein and is rapidly cleaved by intracellular FAAH. Lipoxy-
genase-generated products of AnNH can competitively inhibit
FAAH, which affords an elevated intracellular AnNH concen-
tration. The resulting dissipation of the AnNH gradient ren-
ders the transporter inactive and leads to an enlarged extra-
cellular anandamide concentration. Enhanced CB receptor
stimulation results in prolonged pharmacological activity. On
the other hand, the enhanced CB receptor-induced NO forma-
tion potentiates the transporter protein, which clears AnNH
from the extracellular space. The NO-stimulated accumulation
of AnNH might be further enhanced by the fact that short
pulses of NO are able to inhibit lipoxygenase activity (30), thus
preventing inhibition of FAAH by lipoxygenase-generated hy-
droperoxides of AnNH and congeners. Interestingly, any sig-
naling pathway leading to NO release, either coupled or not
coupled to cannabinoid receptors, might affect AnNH metabo-
lism by activating AnNH (re)uptake. In this perspective, CB1
and/or CB2 receptors might reside on the same cell bearing the
sequestration machinery or on different cells. The autocoid
local inflammation antagonism (41) and the glutamate excito-
toxicity on neurons (42), where AnNH exerts a(nta)gonistic
effects on cannabinoid receptors and nitric oxide is released
(10, 43), might be two relevant processes in which the proposed
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sequestration scheme is operational. It is noteworthy that li-
poxygenase activity is found in processes such as lymphocyte
activation and neuronal cell death, where lipoxygenase activa-
tion (44, 45) might prolong the effects of AnNH (13).
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